Trial Profile

Prospective, randomised, double-blind, double-dummy, placebo-controlled multicenter clinical trial of efficacy and safety with immunotherapy in patients with controlled mild to moderate allergic asthma and rhinitis/rhinoconjunctivitis, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MM 09 (Primary) ; MM 09 (Primary)
Indications Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis
Focus Registrational; Therapeutic Use
Sponsors Inmunotek

02 Jun 2023 This trial has been discontinued (End Date: 09 May 2023), according to European Clinical Trials Database record.
17 Nov 2022 Planned initiation date changed to 1 December 2022.
21 Apr 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com